ClinicalTrials.gg
CompletedNCT03406741HirschsprungUpdated May 8, 2026

Neuropsychological Development and Functional Outcome Sin Children With Hirschsprung Disease at School Age

An interventional study of psychometric evaluation and neuropsychological evaluation in Hirschsprung's Disease (HD), sponsored by Assistance Publique Hopitaux De Marseille. Completed at 1 site in France. Open to participants aged 8 Years to 13 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
8 Years to 13 Years
Sex
All
01

Study summary

Hirschsprung's disease (HD) is a rare congenital disease (1:5000) characterized by neonatal functional low bowel obstruction that is caused by aganglionosis of the distal bowel. HD treatment consists in surgery of colonic reduction in the early childhood, requiring afterward a long-term follow-up. In the long term complications (incontinence, constipation, enterocolitis, soiling)but also iterative anesthesia in childhood and repeated hospitalizations can have negative effects on child's development.

The main aim of the study is to estimate neuropsychological development at school age (6-10 years). Of children operated of HD Secondary aims are evaluation of the neuro-driving development and global health, comparison of quality of life levels to those of French population standards as well as to study the complex relations between on one hand the quality of life of these children and on the other hand the socio-demographic data, the initial clinical elements and the surgical coverage, as well as their health and current cognitive profile.

This multicenter study included pediatric surgery departments of Marseille. All children born between 1/1/2005 and 31/12/2010 and presenting HD represent the population. All the families will be contacted resting on the networks of set up follow-up. A written agreement will be collected with the parents. For all the participating children, a consultation will be organized: quality of life data (reported by children and by their parents in validated standardized questionnaires), clinical examination of the child, cognitive profile of the child. The duration of inclusion is scheduled for 12 months.

This is the first French study using auto-reported data on children's quality of life at school age affected by a HD. The results of this study will allow developing hypotheses on predictive risk factors for neuropsychological development disorders. Besides a better knowledge of the relation existing between these children quality of life and their functional results due to the disease could help clinicians in their medical reflections.

02

Conditions studied

  • Hirschsprung's Disease (HD)

Browse trials for

03

In context

Hirschsprung Disease

63 studies on the registry are indexed under Hirschsprung Disease; 24 are open to participants now.

This study's enrollment of 2 is below the median of 50 across 32 interventional studies indexed under Hirschsprung Disease.

Browse Hirschsprung Disease studies →

Lead sponsor

Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child aged 8 to 13
  • Child with Hirschsprung's disease (diagnosis confirmed by anatomopathological analysis),
  • Child with no severe cerebral palsy
  • Child with no developmental psychosis
  • Child not showing amblyopia
  • Child not deaf hearing
  • Child able to answer a questionnaire in French language,
  • a child whose parents or legal representatives have accepted the principle of participation in this study, and who have signed an ,

Exclusion criteria

Exclusion Criteria:

  • Child deceased between birth and the date of assessment,
  • Child with cerebral palsy
  • Child whose parents or legal representatives refused to allow their child to participate in this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Child with Hirschsprung's disease

    Neuropsychological assessment at elementary school

    Behavioral: psychometric evaluation · Behavioral: neuropsychological evaluation

Interventions

  • Behavioralpsychometric evaluation

    Wechsler type composite scales (WISC)

  • Behavioralneuropsychological evaluation

    Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire

06

What researchers measure

Primary outcomes

  1. Evaluation of a sensory deficit

    Administration d'un test psychometric de type Wechsler. The Wechsler Intelligence Scale for Children (WISC). The WISC-IV includes 15 subtests exploring four major components assessing the different intellectual skills essential to learning processes. The minimum score is 70, the normality between 90 ant 110, the maximum score is 130.

    Time frame: 12 months

Secondary outcomes

  1. Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire (SDQ).

    It includes 25 questions that are asked to parents. It is used within research, evaluating treatment outcome and as part of clinical assessment in order to examine a child's mental well-being. A total difficulties score is calculated using the SDQ, which ranges from 0-40. Each 1 point increase in the total difficulties score corresponds with an increase in the risk of developing a mental health disorder. Categories have been proposed by Youth in Mind authors in order to assess whether a child's score is close to average, slightly above average, high or very high.

    Time frame: 12 months

07

Study locations

1 site
  • Assistance Publique Hôpitaux de Marseille
    Marseille, 13354, France
08

References and documents

Publications

  • Mille E, Dariel A, Louis-Borrione C, Merrot T, Loundou A, Tosello B, Gire C. Quality of life and neuropsychological development at school age in Hirschsprung's disease. J Pediatr Surg. 2020 Aug;55(8):1481-1487. doi: 10.1016/j.jpedsurg.2020.01.005. Epub 2020 Jan 30. PubMed 32063371 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Jan 2019, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2018
First posted
Jan 23, 2018
StartActual
Jan 17, 2018
Primary completionActual
Jan 17, 2019
CompletionActual
May 26, 2023
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03406741
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Jan 17, 2018
Primary completion
Jan 17, 2019
Completion
May 26, 2023
Last update
May 8, 2026

Study contacts

Jean-Olivier ARNAUD, Director
study director · Assistance Publique Hôpitaux de Marseille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion